August 15, 2025Open Access

Targeting von Willebrand factor selectively under inflammatory conditions

View Full Paper

Ask AI

Bookmark

Lumacaftor selectively inhibits von Willebrand factor under oxidizing conditions, reducing bleeding risk and improving therapeutic options.
The study reveals that VWF is activated by oxidizing agents during inflammation, changing how we approach anti-thrombotic therapies.
Testing was done using an enzyme-linked immunosorbent assay, comparing VWF activity in oxidizing and non-oxidizing conditions across several drugs.
This high-throughput assay method enables efficient screening of drug candidates, pointing to significant advancements in targeted anti-thrombotic treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Observational analysis shows lumacaftor inhibits von Willebrand factor in oxidizing conditions, suggesting a novel anti-thrombotic approach.

Interlandi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows lumacaftor inhibits von Willebrand factor in oxidizing conditions, suggesting a novel anti-thrombotic approach.